Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you make the most of staying home.
Visit the hub

For the second time in a week a Canadian drug developer has unveiled plans to list publicly on Nasdaq, the bellwether exchange for biotech companies.

Privately held kidney disease drug developer Chinook Therapeutics Inc., which is jointly headquartered in Vancouver and Seattle, said Tuesday it had agreed to merge with publicly traded immunotherapy developer Aduro Biotech Inc. The deal is effectively a reverse takeover: Aduro will acquire all stock in Chinook from its private backers in exchange for shares, representing about half of Aduro’s outstanding common stock after the deal. But Chinook management will take over the combined entity, which will use the name Chinook Therapeutics.

News of the deal came four days after Montreal precision oncology firm Repare Therapeutics Inc. filed with the U.S. Securities and Exchange Commission to raise US$100-million in an initial public offering. “Biotech is very much alive and well in Canada,” said Jerel Davis, managing director of Versant Ventures, which backed both Chinook and Repare.

Story continues below advertisement

The Chinook-Aduro deal was greeted poorly by Aduro investors. Its stock sold off almost 24 per cent on the day. The company, which had been focused on developing cancer treatments, underwent a strategic review and cost-cutting effort recently and had been exploring strategic alternatives before striking the deal with Chinook. Chinook chief executive Eric Dobmeier said Aduro stock could remain volatile in the short run as shareholders who had invested because it was focused on cancer treatments sell out. “Over the long run we hope investors will see the value of this new focus on kidney disease and the pipeline we have,” he said in an interview.

The combined company will have US$200-million in cash – mostly Aduro’s, with $10-million from Chinook and another US$25-million from its private backers – and three drug candidates to treat rare, chronic kidney treatments affecting hundreds of thousands of people globally: Chinook’s atrasentan, which is set to start key effectiveness trials in humans next year; Aduro’s early-stage antibody BION-1301, which targets the same condition, known as IgA nephropathy; and a third drug in preclinical development.

Mr. Dobmeier called the opportunity to merge with a company that had cash, a drug development program in a similar area and a team managing public listing requirements “pretty unique. You don’t always find all those things in one place.”

Chinook was created last year by Versant at its company-creation lab in Vancouver, where 20 of its 35 employees, including its drug researchers, now work. The intention was to develop “orphan drugs” – those targeted at sufferers of rare, severe chronic kidney disorders for which there were no treatments, a situation that typically leads regulators to allow expedited trials to get drugs to market faster.

The company hired Mr. Dobmeier, a veteran, Seattle-based biotech executive, and raised US$65-million from Versant and two other U.S. private capital firms last year. In January, Chinook said it had licensed worldwide rights to develop atrasentan from U.S. pharma giant AbbVie Inc., which had proved the drug was safe in large-scale human trials for a different application that it abandoned a few years ago. But data subsequently published in the Lancet indicated the AbbVie study would have yielded some positive results had it continued, prompting Chinook to give the drug another shot.

Chinook is one of several companies to find early success in Canada’s flourishing biotechnology sector in recent years. Last year Canadian life sciences companies raised a record $921-million in venture capital and two companies sold out at US$1-billion valuations. Several have raised nine-figure sums to fund development, including lupus drug developer Aurinia Pharmaceuticals Inc., which last week filed the first new drug application in several years by a Canadian firm with the U.S. Food and Drug Administration.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies